Inclusion Criteria:

• Patients are to be greater than 40 kg body weight.
• Patients must have adequate veins to provide intravenous access.

• Women who are not pregnant, lactating, or of childbearing potential. Lack of childbearing potential was defined as:

  • Being post-menopausal
  • Being surgically sterile
  • Practicing contraception
• Patients with childbearing potential had to have a negative serum human chorionic gonadotropin (HCG) upon entrance into the study.
• Patients must be willing to adhere to the protocol, and sign an Informed Patient Consent Form prior to entry into the study.
• Patients must not be on any other investigational device/drug treatment.
• Patients with the diagnosis of mycosis fungoides (MF) including a skin biopsy consistent with MF (atypical epidermotrophic or folliculocentric T-cells).

• Appropriate staging as IA, IB or IIA : T1 or T2 (patches or plaques) with measurable lesions.

  • IA patients must show evidence of a minor blood abnormality by morphology or laboratory assessment.
  • For IIA patients - clinically significant nodes (1.5 cm) must have lymph node biopsy showing dermatopathic nodes or no involvement.
• Patients must be willing and able to discontinue concomitant medications for MF.

• Patients currently taking the following drugs must discontinue medication prior to enrollment in the trial:

  • Psoralens and ultraviolet A (PUVA) or ultraviolet B (UVB) therapy – 4 weeks
  • Topical nitrogen mustard or other topical chemotherapy – 4 weeks
  • Bexarotene capsules or other systemic biologic agent – 3 weeks washout
  • High dose topical steroids, topical retinoids or immunotherapy – 2 week washout with 1% topical hydrocortisone
  • Oral steroids above 10 mg – 30 day washout, unless patient has Addison’s disease or adrenal insufficiency
• Patients must be refractory to at least one of the standard therapies used to treat Stage IA, IB or IIA CTCL such as oral steroids, high-dose topical steroids, mechlorethamine (HN2), bexarotene, PUVA therapy, electron beam radiation, biological response or oral methotrexate.
• Patients must abstain from therapeutic sunbathing, tanning beds, etc. for the duration of the study.

Exclusion Criteria:

• Patients who have MF (T3 cutaneous tumors or T4 exfoliative erythroderma) Stage IIB – IVB, ie. no pathological node or visceral involvement.
• Patients who are unable to tolerate extracorporeal volume loss (e.g., severe cardiac disease or severe anemia or weight < 40 kg).
• Patients with recent (within three months) deterioration of renal function who have a serum creatinine level greater than 3.0 mg/dL.
• Patients with lipemic plasma > 500 ng/dL or uncontrolled diabetes.
• Patients with a history of liver damage (2.5 x normal ALT, AST) or porphyria.
• Patients with positive tests for HIV antibody, hepatitis C virus (HCV) antibody or hepatitis B surface antigen.
• Patients on oral prednisone therapy or full body or high potency topical steroids.
• Women who are pregnant or nursing a child.
• Patients with severe emotional, behavioral or psychiatric problems that, in the opinion of the investigator, would result in poor compliance with the treatment regimen.
• Patients who exhibit idiosyncratic or hypersensitivity reactions to 8-methoxypsoralen compounds, heparin, or citrate.
• Patients with previous exposure to photopheresis therapy.
• Patients who use tanning beds or are receiving phototherapy.